卵巢癌患者循环肿瘤细胞中ERCC1表达与铂类药物敏感性的关系

赵海波, 徐翔, 丁佳佳, 赵恩锋

赵海波, 徐翔, 丁佳佳, 赵恩锋. 卵巢癌患者循环肿瘤细胞中ERCC1表达与铂类药物敏感性的关系[J]. 解放军医学院学报, 2018, 39(4): 279-282. DOI: 10.3969/j.issn.2095-5227.2018.04.003
引用本文: 赵海波, 徐翔, 丁佳佳, 赵恩锋. 卵巢癌患者循环肿瘤细胞中ERCC1表达与铂类药物敏感性的关系[J]. 解放军医学院学报, 2018, 39(4): 279-282. DOI: 10.3969/j.issn.2095-5227.2018.04.003
ZHAO Haibo, XU Xiang, DING Jiajia, ZHAO Enfeng. Relationship between ERCC1 expression of circulating tumor cell and sensitivity to platinum in patients with ovarian cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2018, 39(4): 279-282. DOI: 10.3969/j.issn.2095-5227.2018.04.003
Citation: ZHAO Haibo, XU Xiang, DING Jiajia, ZHAO Enfeng. Relationship between ERCC1 expression of circulating tumor cell and sensitivity to platinum in patients with ovarian cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2018, 39(4): 279-282. DOI: 10.3969/j.issn.2095-5227.2018.04.003

卵巢癌患者循环肿瘤细胞中ERCC1表达与铂类药物敏感性的关系

基金项目: 

吴阶平医学基金(320.6750.16108)

详细信息
    作者简介:

    赵海波,男,在读硕士,医师。Email:zhb493@126.com

    通讯作者:

    赵恩锋,男,硕士,主任医师。Email:301.zhao@163.com

  • 中图分类号: R 687.3

Relationship between ERCC1 expression of circulating tumor cell and sensitivity to platinum in patients with ovarian cancer

Funds: 

Supported by the Wu Jieping Medical Fund (320.6750.16108)

  • 摘要: 目的 研究上皮性卵巢癌(epithelial ovarian cancer,EOC)患者外周血循环肿瘤细胞(circulating tumor cell,CTC)中切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)表达与铂类药物敏感性的关系。 方法 以2015年3月-2017年6月本院诊治的60例EOC患者为研究对象,收集手术后化疗前及3个疗程化疗(卡铂/紫杉醇)后1周内患者外周血,利用纳米滤膜结合RNA原位杂交技术分离检测CTC及ERCC1+CTC,分析ERCC1+CTC与临床特征、铂类药物敏感性的关系。 结果 60例患者中83.3%(50例)检测出CTC,60%(36例)检测出ERCC1+CTC。将36例ERCC1+CTC患者按照化疗前后ERCC1+CTC数目变化分为化疗后ERCC1+CTC数目升高组(ERCC1+CTC-H组,12例)和ERCC1+CTC数目未升高组(ERCC1+CTC-L组,24例),两组年龄、家族史、病理类型、腹水情况、腹水细胞学情况、残余病灶、FIGO分期等临床特征无统计学差异(P均> 0.05),ERCC1+CTC-L组中62.5%(15例)铂类药物敏感,ERCC1+CTC-H组中16.7%(2例)铂类药物敏感,两组差异有统计学意义(P< 0.05)。 结论 外周血循环肿瘤细胞ERCC1阳性可预测铂类药物敏感性。
    Abstract: Objective To study the relationship between the expression of excision repair cross complementation group 1 (ERCC1)in circulating tumor cell (CTC) in peripheral blood of patients with epithelial ovarian cancer (EOC) and the sensitivity to platinum. Methods A total of 60 EOC patients in Chinese PLA General Hospital from March 2015 to June 2016 were enrolled. Peripheral blood of patients was collected before postoperative chemotherapy and within a week after the three courses of chemotherapy(carboplatin/paclitaxel). The Nanofiltration membrane and RNA in situ hybridization technique was used to separate and detect the CTC and ERCC1-positive CTC. The relationship between ERCC1-positive CTC and the sensitivity to platinum was analyzed. Results Of the 60 cases, CTC was observed in 50 cases (83.3%) and ERCC1-positive CTC in 36 cases (60%). According to the quantitative change of ERCC1 + CTC before and after chemotherapy, the 36 patients were divided into elevated ERCC1 + CTC group (ERCC1 + CTC-H group, 12 cases) and non-elevated ERCC1 + CTC group (ERCC1 + CTC-L group, 24 cases). No significant difference was between the two groups in age, family history, histology, ascites, ascites cytology, residual tumor, FIGO stage (P> 0.05). There were 15 cases (62.5%) in ERCC1 + CTC-L group and 2 cases (16.7%) in ERCC1 + CTC-H group were sensitive to platinum, with statistically significant difference between the two groups (P< 0.05). Conclusion The ERCC1 expression of CTC can predict the sensitivity to platinum.
计量
  • 文章访问数:  27
  • HTML全文浏览量:  2
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-01-09
  • 网络出版日期:  2023-11-08

目录

    /

    返回文章
    返回